Xeris Biopharma Holdings, Inc.
XERS · XNASCIK 1867096fmd_05KZDG0ZB229VZ7HDWTR3MW5YQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
Latest annual · FY2025
Millions- Total revenues
- 292
- Operating income
- 25
- Net income
- 1
Latest quarter · Q3 FY2026
Millions- Total revenues
- 107
- Operating income
- 17
- Net income
- 11
Daily close · XERSIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions16.51 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +38.3%
- Revenue, 5 yearsFY2020 to FY2025
- +70.2%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Xeris Biopharma Holdings, Inc. (XERS) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $291.8 million | $203.1 million | +43.7% | 10-K 2026-03-02 · proof |
| Operating income | $24.9 million | -$33.6 million | 10-K 2026-03-02 · proof | |
| Net income | $554,000 | -$54.8 million | 10-K 2026-03-02 · proof | |
| Cash from operating activities | $28.6 million | -$37 million | 10-K 2026-03-02 · proof | |
| Total assets | $383.5 million | $323.1 million | +18.7% | 10-K 2026-03-02 · proof |
| Total liabilities | $369.8 million | $352.7 million | +4.9% | 10-K 2026-03-02 · proof |
| Cash and cash equivalents | $111 million | $71.6 million | +55% | 10-K 2026-03-02 · proof |
| Total debt | $220.3 million | $232.1 million | -5.1% | 10-K 2026-03-02 · proof |
- What was Xeris Biopharma Holdings, Inc. (XERS)'s revenue in fiscal 2025?
- Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $291.8 million for fiscal 2025 (the year ended Dec 31, 2025), against $203.1 million the year before (+43.7%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What was Xeris Biopharma Holdings, Inc. (XERS)'s operating income in fiscal 2025?
- Xeris Biopharma Holdings, Inc. (XERS) reported operating income of $24.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$33.6 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What was Xeris Biopharma Holdings, Inc. (XERS)'s net income in fiscal 2025?
- Xeris Biopharma Holdings, Inc. (XERS) reported net income of $554,000 for fiscal 2025 (the year ended Dec 31, 2025), against -$54.8 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What was Xeris Biopharma Holdings, Inc. (XERS)'s cash from operating activities in fiscal 2025?
- Xeris Biopharma Holdings, Inc. (XERS) reported cash from operating activities of $28.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$37 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What are Xeris Biopharma Holdings, Inc. (XERS)'s total assets?
- As of Dec 31, 2025, Xeris Biopharma Holdings, Inc. (XERS) reported total assets of $383.5 million, against $323.1 million a year earlier (+18.7%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What are Xeris Biopharma Holdings, Inc. (XERS)'s total liabilities?
- As of Dec 31, 2025, Xeris Biopharma Holdings, Inc. (XERS) reported total liabilities of $369.8 million, against $352.7 million a year earlier (+4.9%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What are Xeris Biopharma Holdings, Inc. (XERS)'s cash and cash equivalents?
- As of Dec 31, 2025, Xeris Biopharma Holdings, Inc. (XERS) reported cash and cash equivalents of $111 million, against $71.6 million a year earlier (+55%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What is Xeris Biopharma Holdings, Inc. (XERS)'s total debt?
- As of Dec 31, 2025, Xeris Biopharma Holdings, Inc. (XERS) reported total debt of $220.3 million, against $232.1 million a year earlier (-5.1%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:XERS&period_type=annual&limit=5"Information only, not investment advice.